EVMN ▼ -8.6% - Evommune, Inc. $EVMN - Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Evommune shares fell 8.6% following the company's announcement of a late-breaker presentation of Phase 2a data for its EVO301 atopic dermatitis candidate at the European Academy of Dermatology & Venereology Congress. The market's negative reaction suggests investors may have had concerns about the interim efficacy or safety results, or viewed the late-breaker designation as insufficient to meet prior expectations for the program. 23-SEP-2026 04:14 PM ET